sidebar, Fenix, paladin - In theory it would be nice to only license apabetalone for one medical issue, in practice though it is close to impossible. If you have read all the posters that BDAZ has posted in the last few days you will notice that all of these 3 diseases are closely tied together. DRs may not be absolutely certain that their patient has CVD without dementia or declining kidney function. So who's to stop them from scripting a patient for one thing and really having it for another. It is a challenge. For these reasons it is most likely that one company will end up with the patent/license for all indications. That's not 100%, just most likely.

All three of you are reasonably new posters to the RVX Hub. In the past we have discussed this situation a few times. This argument is what makes the possible selling price for ABL so hard for many to grasp. When you add it all up it is almost impossible to come up with annual sales that wouldn't leave Humara in the dust. It's going to be interesting to see how this all ends up. 

At this point in time to me, the meeting with the FDA on Wednesday could be the single biggest day in the companies history. To bad they won't be able to tell us anything about it for a month or so.

tada